Phase 4 N=39 Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
Atelectasis
Primary: Improvement of Atelectasis — 6; 7; 3; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=157 AVAI: Atrial Ventricular Arrythmia Incidence
Ventricular Tachycardia · Atrial Fibrillation
Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…
Phase 4 N=48 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Phase 3 N=40 Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
HIV Infections
Primary: Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve. — 0.0066; 0.0070 1/h — p=0.43
Phase 3 N=284 A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013) — 88.3; 75.8 percentage of participants
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
Phase 3 N=125 Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale, for DSM-IV (CAPS IV) — -15.97; -11.22 units on a scale — p=> .05
N/A N=5,834 European Mortality & Length Of Intensive Care Unit (ICU) Stay Evaluation (ELOISE)
Critical Illness
Primary: Vital Status at Hospital Discharge — 1232; 165 participants
Phase 3 N=1,015 A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
Chronic Kidney Disease
Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 172; 183 participants
Phase 2 N=606 Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Arthroplasty, Replacement, Hip · Thrombosis
Primary: Prevention of Venous Thromboembolism (VTE) — 13; 13; 10; 13 percentage of patients with event — p=0.238
Phase 3 N=3,445 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Cardiovascular Diseases · Heart Diseases · Heart Failure, Congestive
Primary: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First — 6.6; 5.9 Events…
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
Phase 2 N=45 A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).
Kidney Transplantation
Primary: Percentage of Participants With Acute Rejection — 9.1 percentage of participants
Phase 4 N=276 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Gastroesophageal Reflux Disease
Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants
Phase 2 N=22 Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Objective Response Rate — 1; 7; 11 participants